NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 D-cycloserine and Lurasidone, an oral, fixed dosed combination of D-cycloserine/lurasidone that earned food and drug administration-designated as breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 ketamine, which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior ASIB. The company has a partnership with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

NRX Pharmaceuticals Inc.

The Vanguard Total Stock Market ETF ($VTI) offers broad exposure to large-, mid-, and small-cap U.S. companies, giving investors a stake in the ful...

VTI ETF Daily Update — November 21, 2025

The Vanguard Total Stock Market ETF ($VTI) offers investors broad exposure to the entire U.S. equity market. In today’s VTI ETF snapshot, we break ...

What’s Moving VTI ETF? Daily Snapshot — 11/18/2025

Nrx Pharmaceuticals, Inc. ( ($NRXP) ) has released its Q3 earnings. Here is a breakdown of the information Nrx Pharmaceuticals, Inc. presented to i...

NRx Pharmaceuticals Reports Q3 2025 Financial Results

VTI ETF Daily Update—11/17/2025

VTI ETF Daily Report—11/14/2025

Vanguard Total Stock Market ETF (VTI) Daily Snapshot — 11/13/25

Austin, Texas, United States, November 10th, 2025, FinanceWire NRx Pharmaceuticals (NASDAQ: NRXP), announced that its subsidiary, HOPE Therapeutics...

NRx Pharmaceuticals (NASDAQ: NRXP) Launches HOPE Therapeutics’ One-Day TMS Protocol for Treatment-Resistant Depression in Florida 

The Vanguard Total Stock Market ETF ($VTI) tracks the performance of the entire U.S. equity market. VTI ETF is down 1.88% over the past five days, ...

VTI ETF Daily Report: 11/10/2025

How is the VTI ETF faring? The Vanguard Total Stock Market ETF ($VTI) is a comprehensive fund that enables investors to access the entire U.S. stoc...

VTI ETF Daily Update: What Investors Need to Know – 11/7/2025

How is the VTI ETF faring? Vanguard Total Stock Market ETF ($VTI) is an all-in-one fund that lets investors invest in the entire U.S. stock market....

Current Quarter	$-0.01	Next Quarter	$0.1
Current Year	$-0.95	Next Year	$0.34
QoQ Growth	+1100.0%	YoY Growth	+135.8%
3Y EPS CAGR	N/A	Target Price	$36.50
Consensus	Buy	Upside	+1613.6%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NRXP	$2.13	+4.93%	438.30K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NRXP	$2.13	+4.9%	438.30K
3
4
5
6

NRXP

NRXP

EPS Estimates Overview

Quarterly EPS Estimates

Revenue Analysis

Get NRX Pharmaceuticals Inc. Data in Excel

Get NRX Pharmaceuticals Inc. Data in Excel